Defizite in der behandlung von patienten mit kolorektalem karzinom in Deutschland ergebnisse einer multizentrischen dokumentation von therapiealgorithmen

Translated title of the contribution: Survey-based analysis of treatment algorithms in colorectal cancer discloses deficits in patient care in Germany. Results of a multicentric documentation of treatment algorithms

Axel F Grothey, Lenka Kellermann, Hans Joachim Schmoll

Research output: Contribution to journalArticle

Abstract

Background: Adjuvant chemotherapy for patients with UICC III (Dukes C) colorectal cancer (consensus statements NIH 1990, German Cancer Society 1994) and palliative chemotherapy for metastatic disease have long been recognized to provide a survival benefit in colorectal cancer. However, it remains unclear if these concepts have made inroads into clinical practice. Patients and Methods: Therefore, we asked 74 institutions treating colorectal cancer patients in Germany to document the treatment algorithms of all patients with colorectal cancer seen in the third quarter of 1998. Clinical careers of 1,001 patients (m/f 465/536; median age 62.9 years [28-93]; colon 596, rectum 405; UICC I 117, II 206, III 407, IV 218) were documented. Results: Only 63.4% of patients with UICC III colorectal cancer received adjuvant therapy with a significant difference between hospitals with (67.1%) and without (42.6%) oncological departments (p < 0.01). Higher age appeared to be the most important factor for withholding treatment since 196 of 286 (68.5%) patients < 70 years, but only 57 of 121 (47.1%) > 70 years underwent adjuvant therapy. 78.4% of patients with UICC IV colorectal cancer (91.8% university hospitals, 76.8% hospital with, 50% without oncological departments, 66.7% rehabilitation clinics, 82.4% private practices) received palliative chemotherapy (first line: 5-FU/FA bolus 57%, 5-FU/FA infusion 20%, 5-FU mono 15%). Conclusion: Considering an annual incidence of colorectal cancer in Germany of 52,000 with 30% UICC III, discounting patients > 80 years or ECOG status > 2, and estimating a survival benefit of 10% after adjuvant chemotherapy, approximately 530 lifes are lost annually in Germany due to insufficient treatment of UICC III colorectal cancer based on our survey. In addition, substantial financial demand is generated by the subsequent palliative treatment of potentially curable patients. - In conclusion, survey-based analysis of treatment algorithms can provide valuable insights into clinical practice in oncology and can disclose deficits in patient care as demonstrated here in colorectal cancer.

Original languageGerman
Pages (from-to)144-153
Number of pages10
JournalColoproctology
Volume24
Issue number3
StatePublished - 2002
Externally publishedYes

Fingerprint

Documentation
Germany
Colorectal Neoplasms
Patient Care
Fluorouracil
Therapeutics
Adjuvant Chemotherapy
Surveys and Questionnaires
Drug Therapy
Survival
Private Practice
Palliative Care
Rectum
Colon
Rehabilitation
Incidence

Keywords

  • Adjuvant therapy
  • Colorectal cancer
  • Quality control

ASJC Scopus subject areas

  • Gastroenterology
  • Surgery

Cite this

Defizite in der behandlung von patienten mit kolorektalem karzinom in Deutschland ergebnisse einer multizentrischen dokumentation von therapiealgorithmen. / Grothey, Axel F; Kellermann, Lenka; Schmoll, Hans Joachim.

In: Coloproctology, Vol. 24, No. 3, 2002, p. 144-153.

Research output: Contribution to journalArticle

@article{649eb6844ade41ed9413f0e1acf66d74,
title = "Defizite in der behandlung von patienten mit kolorektalem karzinom in Deutschland ergebnisse einer multizentrischen dokumentation von therapiealgorithmen",
abstract = "Background: Adjuvant chemotherapy for patients with UICC III (Dukes C) colorectal cancer (consensus statements NIH 1990, German Cancer Society 1994) and palliative chemotherapy for metastatic disease have long been recognized to provide a survival benefit in colorectal cancer. However, it remains unclear if these concepts have made inroads into clinical practice. Patients and Methods: Therefore, we asked 74 institutions treating colorectal cancer patients in Germany to document the treatment algorithms of all patients with colorectal cancer seen in the third quarter of 1998. Clinical careers of 1,001 patients (m/f 465/536; median age 62.9 years [28-93]; colon 596, rectum 405; UICC I 117, II 206, III 407, IV 218) were documented. Results: Only 63.4{\%} of patients with UICC III colorectal cancer received adjuvant therapy with a significant difference between hospitals with (67.1{\%}) and without (42.6{\%}) oncological departments (p < 0.01). Higher age appeared to be the most important factor for withholding treatment since 196 of 286 (68.5{\%}) patients < 70 years, but only 57 of 121 (47.1{\%}) > 70 years underwent adjuvant therapy. 78.4{\%} of patients with UICC IV colorectal cancer (91.8{\%} university hospitals, 76.8{\%} hospital with, 50{\%} without oncological departments, 66.7{\%} rehabilitation clinics, 82.4{\%} private practices) received palliative chemotherapy (first line: 5-FU/FA bolus 57{\%}, 5-FU/FA infusion 20{\%}, 5-FU mono 15{\%}). Conclusion: Considering an annual incidence of colorectal cancer in Germany of 52,000 with 30{\%} UICC III, discounting patients > 80 years or ECOG status > 2, and estimating a survival benefit of 10{\%} after adjuvant chemotherapy, approximately 530 lifes are lost annually in Germany due to insufficient treatment of UICC III colorectal cancer based on our survey. In addition, substantial financial demand is generated by the subsequent palliative treatment of potentially curable patients. - In conclusion, survey-based analysis of treatment algorithms can provide valuable insights into clinical practice in oncology and can disclose deficits in patient care as demonstrated here in colorectal cancer.",
keywords = "Adjuvant therapy, Colorectal cancer, Quality control",
author = "Grothey, {Axel F} and Lenka Kellermann and Schmoll, {Hans Joachim}",
year = "2002",
language = "German",
volume = "24",
pages = "144--153",
journal = "Coloproctology",
issn = "0174-2442",
publisher = "Urban und Vogel",
number = "3",

}

TY - JOUR

T1 - Defizite in der behandlung von patienten mit kolorektalem karzinom in Deutschland ergebnisse einer multizentrischen dokumentation von therapiealgorithmen

AU - Grothey, Axel F

AU - Kellermann, Lenka

AU - Schmoll, Hans Joachim

PY - 2002

Y1 - 2002

N2 - Background: Adjuvant chemotherapy for patients with UICC III (Dukes C) colorectal cancer (consensus statements NIH 1990, German Cancer Society 1994) and palliative chemotherapy for metastatic disease have long been recognized to provide a survival benefit in colorectal cancer. However, it remains unclear if these concepts have made inroads into clinical practice. Patients and Methods: Therefore, we asked 74 institutions treating colorectal cancer patients in Germany to document the treatment algorithms of all patients with colorectal cancer seen in the third quarter of 1998. Clinical careers of 1,001 patients (m/f 465/536; median age 62.9 years [28-93]; colon 596, rectum 405; UICC I 117, II 206, III 407, IV 218) were documented. Results: Only 63.4% of patients with UICC III colorectal cancer received adjuvant therapy with a significant difference between hospitals with (67.1%) and without (42.6%) oncological departments (p < 0.01). Higher age appeared to be the most important factor for withholding treatment since 196 of 286 (68.5%) patients < 70 years, but only 57 of 121 (47.1%) > 70 years underwent adjuvant therapy. 78.4% of patients with UICC IV colorectal cancer (91.8% university hospitals, 76.8% hospital with, 50% without oncological departments, 66.7% rehabilitation clinics, 82.4% private practices) received palliative chemotherapy (first line: 5-FU/FA bolus 57%, 5-FU/FA infusion 20%, 5-FU mono 15%). Conclusion: Considering an annual incidence of colorectal cancer in Germany of 52,000 with 30% UICC III, discounting patients > 80 years or ECOG status > 2, and estimating a survival benefit of 10% after adjuvant chemotherapy, approximately 530 lifes are lost annually in Germany due to insufficient treatment of UICC III colorectal cancer based on our survey. In addition, substantial financial demand is generated by the subsequent palliative treatment of potentially curable patients. - In conclusion, survey-based analysis of treatment algorithms can provide valuable insights into clinical practice in oncology and can disclose deficits in patient care as demonstrated here in colorectal cancer.

AB - Background: Adjuvant chemotherapy for patients with UICC III (Dukes C) colorectal cancer (consensus statements NIH 1990, German Cancer Society 1994) and palliative chemotherapy for metastatic disease have long been recognized to provide a survival benefit in colorectal cancer. However, it remains unclear if these concepts have made inroads into clinical practice. Patients and Methods: Therefore, we asked 74 institutions treating colorectal cancer patients in Germany to document the treatment algorithms of all patients with colorectal cancer seen in the third quarter of 1998. Clinical careers of 1,001 patients (m/f 465/536; median age 62.9 years [28-93]; colon 596, rectum 405; UICC I 117, II 206, III 407, IV 218) were documented. Results: Only 63.4% of patients with UICC III colorectal cancer received adjuvant therapy with a significant difference between hospitals with (67.1%) and without (42.6%) oncological departments (p < 0.01). Higher age appeared to be the most important factor for withholding treatment since 196 of 286 (68.5%) patients < 70 years, but only 57 of 121 (47.1%) > 70 years underwent adjuvant therapy. 78.4% of patients with UICC IV colorectal cancer (91.8% university hospitals, 76.8% hospital with, 50% without oncological departments, 66.7% rehabilitation clinics, 82.4% private practices) received palliative chemotherapy (first line: 5-FU/FA bolus 57%, 5-FU/FA infusion 20%, 5-FU mono 15%). Conclusion: Considering an annual incidence of colorectal cancer in Germany of 52,000 with 30% UICC III, discounting patients > 80 years or ECOG status > 2, and estimating a survival benefit of 10% after adjuvant chemotherapy, approximately 530 lifes are lost annually in Germany due to insufficient treatment of UICC III colorectal cancer based on our survey. In addition, substantial financial demand is generated by the subsequent palliative treatment of potentially curable patients. - In conclusion, survey-based analysis of treatment algorithms can provide valuable insights into clinical practice in oncology and can disclose deficits in patient care as demonstrated here in colorectal cancer.

KW - Adjuvant therapy

KW - Colorectal cancer

KW - Quality control

UR - http://www.scopus.com/inward/record.url?scp=0036065883&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036065883&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:0036065883

VL - 24

SP - 144

EP - 153

JO - Coloproctology

JF - Coloproctology

SN - 0174-2442

IS - 3

ER -